Ju Bo Liu
Directeur/Membre du Conseil chez BIOTON S.A.
Profil
Ju Bo Liu is the founder.
He founded Beijing Novotek Medicinal Technology Development Co. Ltd.
in 2009 and Jcs Biopolytech, Inc. in 2005.
Dr. Liu is also the founder of NovoTek Pharmaceuticals Ltd.
Dr. Liu's current job(s) include being the Chief Executive Officer at Novotek Medicinal Technology Development Co. Ltd.
since 2009, a Director at ITabMed Co., Ltd., and a Member-Supervisory Board at BIOTON SA since 2022.
Dr. Liu's former job(s) include being the Chief Executive Officer at NovoTek Therapeutics, Inc. from 2009 to 2018, a Non-Executive Director at SciGen Pte Ltd.
from 2017 to 2018, and a Director of Marketing & Regulatory Affairs at Huayuanlong Medicinal Technology Development Co. Ltd.
from 1997 to 2001.
Dr. Liu obtained a doctorate degree from the University of Toronto in 2006 and an undergraduate degree from Shenyang Pharmaceutical University in 1997.
Postes actifs de Ju Bo Liu
| Sociétés | Poste | Début |
|---|---|---|
| BIOTON S.A. | Directeur/Membre du Conseil | 01/01/2022 |
NovoTek Pharmaceuticals Ltd.
 NovoTek Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Yifan Pharmaceutical Co., Ltd., NovoTek Pharmaceuticals Ltd. is a Chinese pharmaceutical company that manufactures pharmaceutical products. The company is based in Hong Kong, Hong Kong. The company was founded by Ju Bo Liu. Ju Bo Liu has been the CEO since incorporation. NovoTek Pharmaceuticals was acquired by Yifan International Pharmaceutical Co., Ltd. from Merrylake International Ltd. on January 25, 2018 for $20.60 million. | Directeur Général | - |
| Novotek Medicinal Technology Development Co. Ltd. | Directeur Général | 01/08/2009 |
| Beijing Novotek Medicinal Technology Development Co. Ltd. | Directeur Général | 01/09/2009 |
Itabmed Co., Ltd.
 Itabmed Co., Ltd. BiotechnologyHealth Technology ITabMed Co., Ltd. is a Chinese clinical-stage biotech company that focuses on the discovery and development of immunotherapy products to treat cancer. The company is based in Shanghai, China. ITabMed Co. was founded in 2020 by Xiaoqiang Yan, who has been the CEO since 2020. | Directeur/Membre du Conseil | - |
Anciens postes connus de Ju Bo Liu
| Sociétés | Poste | Fin |
|---|---|---|
| SCIGEN LIMITED | Directeur/Membre du Conseil | 07/08/2018 |
| NovoTek Therapeutics, Inc. | Directeur Général | 01/03/2018 |
| Huayuanlong Medicinal Technology Development Co. Ltd. | Conseiller Juridique Général | 01/02/2001 |
Formation de Ju Bo Liu
| University of Toronto | Doctorate Degree |
| Shenyang Pharmaceutical University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BIOTON S.A. | Health Technology |
| Entreprise privées | 7 |
|---|---|
SciGen Pte Ltd.
 SciGen Pte Ltd. Pharmaceuticals: MajorHealth Technology SciGen Pte Ltd. engages in the development, manufacturing, and marketing of biopharmaceutical products. It operates through following segments: Singapore, Australia, Korea, Thailand, Philippines, China, and Others. The Singapore segment comprises of corporate office functions, sales, and marketing. The Australia, Korea, Thailand, and Philippines segments deal with sales and marketing activities. The China segment is involved in regulatory activities. The Others segment covers operations on in Indonesia, Pakistan, Vietnam, Hong Kong, Myanmar, Malaysia, and profit sharing income on sale of insulin. The firm's products include SciLin, SciTropin A, SciLocyte, SciTrace 5 Injection, and Heri Injection. The company was founded by Saul Akerib Mashaal in 1988 and is headquartered in Singapore. | Health Technology |
| NovoTek Therapeutics, Inc. | |
NovoTek Pharmaceuticals Ltd.
NovoTek Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Yifan Pharmaceutical Co., Ltd., NovoTek Pharmaceuticals Ltd. is a Chinese pharmaceutical company that manufactures pharmaceutical products. The company is based in Hong Kong, Hong Kong. The company was founded by Ju Bo Liu. Ju Bo Liu has been the CEO since incorporation. NovoTek Pharmaceuticals was acquired by Yifan International Pharmaceutical Co., Ltd. from Merrylake International Ltd. on January 25, 2018 for $20.60 million. | Health Technology |
| Novotek Medicinal Technology Development Co. Ltd. | |
| Huayuanlong Medicinal Technology Development Co. Ltd. | |
| Beijing Novotek Medicinal Technology Development Co. Ltd. | |
Itabmed Co., Ltd.
Itabmed Co., Ltd. BiotechnologyHealth Technology ITabMed Co., Ltd. is a Chinese clinical-stage biotech company that focuses on the discovery and development of immunotherapy products to treat cancer. The company is based in Shanghai, China. ITabMed Co. was founded in 2020 by Xiaoqiang Yan, who has been the CEO since 2020. | Health Technology |
